Pfizer breaks away from pack in pharma league table

Related tags Cent Pharmaceutical industry Ims health Pfizer

US pharmaceutical major Pfizer reinforced its position as the
world's largest drug company in 2002 after putting in sales of
$29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the
prior year, according to a new analysis by IMS Health. And the firm
will likely extend its lead in 2003, now that it has completed its
$60-billion acquisition of Pharmacia, in tenth place in the
rankings with sales of $12.26 billion (+8 per cent).

US pharmaceutical major Pfizer reinforced its position as the world's largest drug company in 2002 after putting in sales of $29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the prior year, according to a new analysis by IMS Health. And the firm will likely extend its lead in 2003, now that it has completed its $60-billion acquisition of Pharmacia, in tenth place in the rankings with sales of $12.26 billion (+8 per cent).

Europe's largest drugmaker, GlaxoSmithKline, came second in the league table with sales of $27.88 billion, but lagged in terms of growth with a 7 per cent hike over 2001. Merck & Co, for many years the number one company but which has slipped down the rankings after eschewing the merger-mania of the 1990s, came in third with sales of $19.97 billion, up 6 per cent.

In terms of revenue growth, fourth-placed Johnson & Johnson led the group, with sales up 15 per cent to $18.55 billion. AstraZeneca's $18.12 billion turnover (+9 per cent) gave it the fifth spot, followed by Novartis ($16.6 billion; +13 per cent) and Aventis ($14.30 billion; +11 per cent).

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars